Literature DB >> 11889499

Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics.

Andreas Stevens1, Jürgen Schwarz, Benedikt Schwarz, Ilona Ruf, Thomas Kolter, Joerg Czekalla.   

Abstract

OBJECTIVE: Novel and classic neuroleptics differ in their effects on limbic striatal/nucleus accumbens (NA) and prefrontal cortex (PFC) dopamine turnover, suggesting differential effects on implicit and explicit learning as well as on anhedonia. The present study investigates whether such differences can be demonstrated in a naturalistic sample of schizophrenic patients.
METHODS: Twenty-five inpatients diagnosed with DSM-IV schizophrenic psychosis and treated for at least 14 days with the novel neuroleptic olanzapine were compared with 25 schizophrenics taking classic neuroleptics and with 25 healthy controls, matched by age and education level. PFC/NA-dependent implicit learning was assessed by a serial reaction time task (SRTT) and compared with cerebellum-mediated classical eye-blink conditioning and explicit visuospatial memory. Anhedonia was measured with the Snaith-Hamilton-Pleasure Scale (SHAPS).
RESULTS: Implicit (SRTT) and psychomotor speed, but not explicit (visuospatial) learning were superior in the olanzapine-treated group as compared to the patients on classic neuroleptics. Compared to healthy controls, olanzapine-treated schizophrenics showed similar implicit learning, but reduced explicit (visuospatial) memory performance. Acquisition of eyeblink conditioning was not different between the three groups. There was no difference with regard to anhedonia and SANS scores between the patients.
CONCLUSION: Olanzapine seems to interfere less with unattended learning and motor speed than classical neuroleptics. In daily life, this may translate into better adaptation to a rapidly changing environment. The effects seem specific, as in explicit learning and eyeblink conditioning no difference to classic NL was found.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889499     DOI: 10.1007/s00213-001-0974-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  16 in total

1.  Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.

Authors:  James I Wasserman; Rebecca J Barry; Lisa Bradford; Nicholas J Delva; Richard J Beninger
Journal:  Psychopharmacology (Berl)       Date:  2012-01-12       Impact factor: 4.530

2.  Patients with schizophrenia demonstrate inconsistent preference judgments for affective and nonaffective stimuli.

Authors:  Gregory P Strauss; Benjamin M Robinson; James A Waltz; Michael J Frank; Zuzana Kasanova; Ellen S Herbener; James M Gold
Journal:  Schizophr Bull       Date:  2010-05-19       Impact factor: 9.306

Review 3.  Turning it upside down: areas of preserved cognitive function in schizophrenia.

Authors:  James M Gold; Britta Hahn; Gregory P Strauss; James A Waltz
Journal:  Neuropsychol Rev       Date:  2009-05-19       Impact factor: 7.444

4.  Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.

Authors:  Scot E Purdon; Neil Woodward; Stacy R Lindborg; Emmanuel Stip
Journal:  Psychopharmacology (Berl)       Date:  2003-06-24       Impact factor: 4.530

5.  Incidental and intentional sequence learning in youth-onset psychosis and Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Canan Karatekin; Tonya White; Christopher Bingham
Journal:  Neuropsychology       Date:  2009-07       Impact factor: 3.295

6.  Cerebellar motor learning deficits in medicated and medication-free men with recent-onset schizophrenia.

Authors:  Michael Coesmans; Christian H Röder; Albertine E Smit; Sebastiaan K E Koekkoek; Chris I De Zeeuw; Maarten A Frens; Josef N van der Geest
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

7.  Anhedonia and substance dependence: clinical correlates and treatment options.

Authors:  Daniele Stavros Hatzigiakoumis; Giovanni Martinotti; Massimo Di Giannantonio; Luigi Janiri
Journal:  Front Psychiatry       Date:  2011-03-17       Impact factor: 4.157

8.  The neuropharmacology of implicit learning.

Authors:  Julia Uddén; Vasiliki Folia; Karl Magnus Petersson
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

Review 9.  The role of the cerebellum in schizophrenia: an update of clinical, cognitive, and functional evidences.

Authors:  Hernàn Picard; Isabelle Amado; Sabine Mouchet-Mages; Jean-Pierre Olié; Marie-Odile Krebs
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

10.  Diabetes and cognitive deficits in chronic schizophrenia: a case-control study.

Authors:  Mei Han; Xu-Feng Huang; Da Chun Chen; Meihong Xiu; Thomas R Kosten; Xiang Yang Zhang
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.